Core One Labs Inc.: Core One Labs Completes Sale of Non-Core Assets
Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the
Company or
Core One ) is pleased to announce that further to its October 30, 2020 press release, the Company has completed the sale of certain of its non-core assets and subsidiaries in California for CAD$3,000,000 plus the assumption of approximately USD$4,000,000 in related liabilities.
The completion of this sale allows the Company to focus its core business on the continued development of psychedelic alternative medicines and experiential therapies, and its CannaStrip
TM delivery technology.
Core One Labs Announces Breakthrough in Solving Psilocybin Dosing Problems by Introducing Biosynthetic Psilocybin to its Patented Thinstrip Delivery Method
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
Leading Microbiologist, Dr Robert E W Hancock Appointed as Executive Chairman of Core One Labs
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
Core One Labs Completes Acquisition of Vocan Biotechnologies Inc
hawaiitelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hawaiitelegraph.com Daily Mail and Mail on Sunday newspapers.
Core One Labs Inc.: Core One Labs Signs Definitive Agreement for Acquisition of Biosynthetic Psilocybin Research Firm Vocan Biotechnologies Inc.
Core One Labs Inc. (CSE:COOL), (OTC:CLABF), (Frankfurt:LD62), (WKN:A14XHT) (the
Company ) is pleased to announce that, further to its press release of October 7, 2020, it has entered into a definitive share purchase agreement (the
Purchase Agreement ), dated December 23, 2020, for the acquisition (the
Acquisition ) of all of the outstanding share capital of Vocan Biotechnologies Inc. (
Vocan ), a Canadian-based genetic engineering and biosynthesis research firm developing a proprietary low cost production method to biosynthesize GMP grade psilocybin.
Vocan s mission is to use science and proprietary technology to advance the knowledge of natural-based medicines for the treatment of mental health illnesses, and addictions. Vocan s team of scientists, specializing in protein expression and biosynthetic fermentation, have discovere